 haemopoiet growth factor avail recombin haemopoiet growth factor precis vitro experi human vivo studi gener result accord expect previou vitro studi clinic exploit haemopoiet growth factor great promis care studi valu effect growth factor multipl complex improv blood cell count se benefici patient circumst control trial clinic end-point essenti situat chemotherapy-induc neutropenia larg studi improv mortal morbid field cancer therapi major benefit haemopoiet growth factor dosag escal consequ improv respons rate long-term surviv care patient select larg multicentr trial like studi develop sever thrombocytopenia effect mean elus thrombopoietin possibl haemopoiet growth factor adjunct treatment sever infect trial possibl fraught difficulti studi date use singl factor begin use factor synergist combin efficaci toxic